Alpha 2.0
Login Register
» Authors » M V Mateos

M V Mateos

Explore the profile of M V Mateos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 1809
Followers 0
Related Specialties
Oncology
Hematology
General Surgery
Top 10 Co-Authors
J F San Miguel
R Garcia-Sanz
M Gonzalez
A Balanzategui
M C Chillon
R Lopez-Perez
M A Dimopoulos
M D Caballero
A Orfao
I Alaejos
Published In
Leukemia
Bone Marrow Transplant
Ann Oncol
Haematologica
Blood Cancer J
Affiliations
Soon will be listed here.
Recent Articles
1.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa J, Ariceta B, Jimenez C, et al.
Blood Cancer J . 2024 Apr; 14(1):74. PMID: 38684670
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based...
2.
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
Dimopoulos M, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G, et al.
Ann Oncol . 2022 Jul; 33(9):988. PMID: 35810138
No abstract available.
3.
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
Dimopoulos M, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G, et al.
Ann Oncol . 2021 Dec; 33(1):117. PMID: 34857439
No abstract available.
4.
Dexamethasone as a partner of isatuximab
Mateos M, Gonzalez-Calle V
Blood . 2021 Mar; 137(9):1133-1134. PMID: 33661291
No abstract available.
5.
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dimopoulos M, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G, et al.
Ann Oncol . 2021 Feb; 32(3):309-322. PMID: 33549387
No abstract available.
6.
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Caballero-Velazquez T, Calderon-Cabrera C, Lopez-Corral L, Puig N, Marquez-Malaver F, Perez-Lopez E, et al.
Bone Marrow Transplant . 2019 Sep; 55(2):419-430. PMID: 31551517
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients...
7.
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, et al.
Leukemia . 2019 Mar; 33(4):1058-1059. PMID: 30842604
Following the publication of this article the authors noted that the MRD data under the Table 1 column "Remark" of Aspire should go to that of Pollux. The authors wish...
8.
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Sanoja-Flores L, Flores-Montero J, Garces J, Paiva B, Puig N, Garcia-Mateo A, et al.
Blood Cancer J . 2018 Nov; 8(12):117. PMID: 30455467
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma...
9.
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, et al.
Leukemia . 2017 Dec; 32(2):252-262. PMID: 29257139
Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM relapse/progression. Recent major randomized controlled trials...
10.
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Kumar S, Dimopoulos M, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al.
Leukemia . 2017 Jun; 31(11):2443-2448. PMID: 28620163
Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have...